Oligonucleotide-based array CGH as a diagnostic tool in multiple myeloma patients

Klinicka Onkologie

Volumn 24, Issue SUPPL., 2011, Pages

  Smetana, Jan ^a   Frohlich J ^a   Vranova V ^a   Mikulasova A ^a   Kuglik P ^a   Hajek R ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Array CGH; Cytogenetics; Multiple myeloma

Indexed keywords

BORTEZOMIB; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN D3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GENOMIC DNA; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; THALIDOMIDE; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR MAF B; UNCLASSIFIED DRUG;

ARRAY BASED COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CARCINOGENESIS; CHROMOSOME 11Q; CHROMOSOME 15; CHROMOSOME 16Q; CHROMOSOME 19; CHROMOSOME 20Q; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 4P; CHROMOSOME 5; CHROMOSOME 6P; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME G BAND; CHROMOSOME TRANSLOCATION; CLONAL VARIATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DIPLOIDY; DNA MICROARRAY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HUMAN; MULTIPLE MYELOMA; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; HUMANS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 79959993875     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Stewart AK, Bergsagel PL, Greipp PR et al A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21(3): 529-534.
2. Debes-Marun CS, Dewald GW, Bryant S et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17(2): 427-436. (Pubitemid 36266921)
3. Harrison CJ, Mazzullo H, Cheung KL et al. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. Br J Haematol 2003; 120(6): 944-952. (Pubitemid 36411552)
4. Fonseca R, Debes-Marun CS, Picken EB et al The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102(7): 355-357.
5. Moreau P, Facon T, Leleu X et al Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100(5): 1579-1583. (Pubitemid 34925131)
6. Gutiérrez NC, Castellanos MV, Martin ML et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation. t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21(1): 143-150. (Pubitemid 44921845)
7. Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64(4): 1546-1558. (Pubitemid 38235629)
8. Smadja NV, Bastard C, Brigaudeau C et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98(7): 2229-2238.
9. Sawyer JR, Tricot G, Mattox S et al. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 91(5): 1732-1741. (Pubitemid 28110339)
10. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005, 10 (Suppl 1): 117-126. (Pubitemid 41829514)
11. Solinas-Toldo S, Lampel S, Stilgenbauer S et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997; 20(4): 399-407. (Pubitemid 27520090)
12. De Wine A, Nair M, Mehta K et al. 60-mer Oligo-Based ComparativeGenomic Hybndization.2006. Available from http://www.chem.agilentcom/Library/ applications/CGH-ApplicationNote-5989-4530EN-72dpi(RGB).pdf〉.
13. Shinawi M, Cheung SW. The array CGH and its clinical applications Drug Discov Today 2008; 13(17-18): 760-770
14. Carter NP. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 2007; 39 (Suppl 7): S16-S21. (Pubitemid 47014471)
15. Kay NE, Eckel-Passow JE, Braggio E et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy Cancer Genet Cytogenet 2010; 203(2): 161-168.
16. Remke M, Pfister S, Kox C et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009; 114(5): 1053-1062
17. Jarosova M, Urbankova H, Plachy R et al. Gain of chromosome 2p in chronic lymphocytic leukemia significant heterogeneity and a new recurrent dicentric rearrangement. Leuk Lymphoma 2010; 51(2): 304-313.
18. Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma Blood 2006; 108(6): 2020-2028.
19. Shaughnessy JD Jr, Zhan F, Burington BE et al A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109(6): 2276-2284. (Pubitemid 46425864)
20. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149(3): 334-351.
21. Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12(2): 131-144. (Pubitemid 47208626)
22. Carter NP. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 2007; 39 (Suppl 7): S16-S21. (Pubitemid 47014471)
23. Theisen A. Microarray-based comparative genomic hybridization (aCGH) 2008. Nature Education 1(1). Available from: http://www.nature.com/scitable/ topicpage/microarray-based-comparative-genomic-hybridization-acgh-45432〉.
24. Fonseca R, Bergsagel PL, Drach J et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23(12): 2210-2221.
25. Largo C, Saéz B, Alvarez S et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica 2006; 92(6): 795-802. (Pubitemid 350155305)
26. Avet-Loiseau H, Andree-Ashley LE, Moore D 2nd et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 1997; 19(2): 124-133.
27. Gutiérrez NC, Hernández JM, García JL et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001; 15(5): 840-845. (Pubitemid 32492709)
28. Liebisch P, Vlardot A, Bassermann N et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 2003; 122(2): 193-201 (Pubitemid 36859603)
29. Gutiérrez NC, García JL, Hernández JM et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104(9): 2661-2666. (Pubitemid 39434945)
30. Carrasco D, Tonon G, Huang Y et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9(4): 313-325.
31. Chng WJ, Gertz MA, Chung T et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24(4): 833-842.
32. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28(30): 4630-4634.
33. Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood 2007; 109(8): 3489-3495
34. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing Nat Genet 2008; 40(6): 722-729.
35. Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471(7339): 467-472.